This study is in concordance with our finding where SHH-N supports only androgen-independent cell growth and therefore this therapy could prove efficient only for CRPC that relies on the SHH-N–AR interaction, or in combination with ADT for advanced prostate cancer to prevent the interaction from occurring and enabling androgen-independent growth. The gene discussed is AR; the disease is Familial prostate cancer.